Treatment of Central Diabetes Insipidus in Pregnancy
Clinical scenario
This protocol addresses central diabetes insipidus (CDI) arising in the context of pregnancy — a setting that presents two distinct patterns: de novo gestational CDI appearing for the first time during gestation, and pre-existing partial CDI that becomes clinically apparent due to pregnancy-related physiological changes.
Why pregnancy changes the picture
CDI may develop de novo during pregnancy, for example in association with conditions affecting the pituitary. Separately, pre-existing partial CDI — previously subclinical — can be unmasked by the metabolic actions of placental cysteine aminopeptidase (vasopressinase), an enzyme that markedly increases the clearance of arginine vasopressin (AVP). The combination means that both newly diagnosed and previously known patients require specific consideration during gestation and the postpartum period.
Treatment approach (partial overview)
Management centres on a synthetic vasopressin analogue that, unlike AVP itself, is resistant to degradation by placental vasopressinase — making it the appropriate agent for this setting. Patients with pre-existing CDI entering pregnancy may need a different management strategy than those with de novo gestational onset. In transient, pregnancy-associated cases, treatment duration is typically time-limited beyond delivery.
The complete sequenced regimen, dosing guidance, and postpartum management algorithm are available in the full protocol.
References
DOI: 10.1210/clinem/dgac381
- CDI may develop de novo during pregnancy due to conditions such as lymphocytic hypophysitis.
- In addition, pre-existing partial CDI may become clinically apparent due to the metabolic actions of placental cysteine aminopeptidase, an enzyme which increases metabolic clearance of oxytocin and AVP.
- Transient pregnancy associated diabetes insipidus is treated with dDAVP, which can usually be withdrawn within 2 months of delivery.
- dDAVP is not broken down by cysteine aminopeptidase, and is therefore indicated as treatment of gestational diabetes insipidus, though some patients with pre-existing CDI may require higher doses of dDAVP.
View source ↗